SCAP and infection: SCAPML2 is characterized by immunosuppression, specific comorbidities, and specific pathogenic infections, with a mortality rate as high as 54.62%, which is significantly higher than the 43% mortality rate of sCAP patients reported in prior research (Reyes et al., 2025).